Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market ...